Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

Veronika Buxhofer-Ausch, Andreas Reiter, Ciprian Tomuleasa, Albert Woelfler, Lino Teichmann, Luminita Ocroteala, Krauth Maria-Theresa, Charu Charu, Stefanie Schlager, Victoria Empson, Christoph Klade, Kurt Krejcy, Heinz Gisslinger, Steffen Koschmieder

Blood (2025) 146 (Supplement 1): 2032.

https://doi.org/10.1182/blood-2025-2032

Published: 2025

Journal Articles

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Blood (2025) 146 (Supplement 1): 485.

https://doi.org/10.1182/blood-2025-485

Published: 2025

Journal Articles

Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across Austria

Blood (2025) 146 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2025-4584

Published: 2025

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Blood (2024) 144 (14): 1486–1495.

https://doi.org/10.1182/blood.2023023780

Published: 2024

Includes: Supplemental data

Journal Articles

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Blood (2023) 141 (8): 917–929.

https://doi.org/10.1182/blood.2022016846

Published: 2023

Includes: Supplemental data

Journal Articles

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Jakob D. Rudzki, Ulrich Jaeger, Dominik Wolf, Andreas Petzer, Richard Greil, Christina Peters, Hildegard T. Greinix, Andishe Attarbaschi, Veronika Buxhofer-Ausch, Michael Girschikofsky, Wolfgang Holter, Michael Leisch, Peter Neumeister, Peter Schlenke, Clemens A. Schmitt, Wolfgang Schwinger, Nina Worel, Philipp Wohlfarth

Blood (2022) 140 (Supplement 1): 6661–6663.

https://doi.org/10.1182/blood-2022-167603

Published: 2022

Journal Articles

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Felix Keil, Antonia Maria Susanne Müller, Andrea Berghold, Veronika Buxhofer-Ausch, Judith Schuster, Regina Riedl, Corinne Vorburger, Alexandra Boehm, Michael Panny, Thomas Noesslinger, Richard Greil, Panagiotis Samaras, Thomas Pabst

Blood (2022) 140 (Supplement 1): 1180–1182.

https://doi.org/10.1182/blood-2022-157917

Published: 2022

Journal Articles

Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Lucas Kühne, Dennis A. Eichenauer, Paul Knöbl, Linus A. Völker, Jessica Kaufeld, Ralph Wendt, Holger Hägele, Thomas Osterholt, Marcus Bieringer, Veronika Buxhofer-Ausch, Jan Menne, Ulf Schoenermarck, Paul Brinkkoetter

Blood (2021) 138 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2021-151283

Published: 2021

Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Blood (2018) 132 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2018-99-118584

Published: 2018

Journal Articles

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

Martin Schalling, Andreas Gleiss, Bettina Gisslinger, Albert Wölfler, Veronika Buxhofer-Ausch, Georg Jeryczynski, MD, Maria-Theresa Krauth, MD, Ingrid Simonitsch-Klupp, MD, Christine Beham-Schmid, Jurgen Thiele, Heinz Gisslinger

Blood (2017) 130 (Supplement 1): 4201.

https://doi.org/10.1182/blood.V130.Suppl_1.4201.4201

Published: 2017

Journal Articles

Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis

Georg Jeryczynski, MD, Albert Woelfler, MD, Bettina Gisslinger, Martin Schalling, Sonja Burgstaller, MD, Veronika Buxhofer-Ausch, Maria Theresa Krauth, MD, Klaus Geissler, MD, Ernst Schlögl, MD, Thamer Sliwa, MD, Ana-Iris Schiefer, MD, Leonhard Muellauer, MD, Ingrid Simonitsch-Klupp, MD, Christine Beham-Schmid, MD, Jürgen Thiele, MDPhD, Heinz Gisslinger

Blood (2016) 128 (22): 1932.

https://doi.org/10.1182/blood.V128.22.1932.1932

Published: 2016

Journal Articles

Influence of Platelet and White Blood Cell Counts until Major Thrombosis: Analysis from a Patient Registry in Essential Thrombocythemia

Veronika Buxhofer-Ausch, Michael Steurer, Siegfried Sormann, Ernst Schloegel, Wolfgang Schimetta, Bettina Gisslinger, Reinhard Ruckser, Martin Schalling, MSc, Guenther A. Gastl, MD, Heinz Gisslinger, MD

Blood (2015) 126 (23): 2814.

https://doi.org/10.1182/blood.V126.23.2814.2814

Published: 2015

Journal Articles

Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia

Tiziano Barbui, MD, Alessandro M. Vannucchi, Veronika Buxhofer-Ausch, Valerio De Stefano, MD, Silvia Betti, MD, Alessandro Rambaldi, Elisa Rumi, MD, Marco Ruggeri, MD, Francesco Rodighiero, Maria Luigia Randi, Irene Bertozzi, Heinz Gisslinger, MD, Guido Finazzi, MD, Alessandra Carobbio, Juergen Thiele, MD, Francesco Passamonti, MD, Chiara Falcone, Ayalew Tefferi, MD

Blood (2015) 126 (23): 4055.

https://doi.org/10.1182/blood.V126.23.4055.4055

Published: 2015

Journal Articles

Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient

Blood (2015) 126 (23): 4056.

https://doi.org/10.1182/blood.V126.23.4056.4056

Published: 2015

Journal Articles

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Blood (2015) 126 (23): 1603.

https://doi.org/10.1182/blood.V126.23.1603.1603

Published: 2015

Journal Articles

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Heinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, Josef Thaler, Ernst Schloegl, Guenther A. Gastl, Dominik Wolf, Robert Kralovics, Bettina Gisslinger, Karin Strecker, Alexander Egle, Thomas Melchardt, Sonja Burgstaller, Ella Willenbacher, Martin Schalling, Nicole C. Them, Pavla Kadlecova, Christoph Klade, Richard Greil

Blood (2015) 126 (15): 1762–1769.

https://doi.org/10.1182/blood-2015-04-637280

Published: 2015

Includes: Supplemental data

Journal Articles

Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia

Heinz Gisslinger, MD, Juergen Thiele, MD PhD, Bettina Gisslinger, MSc, Tiina Berg, B.Sc., Martin Schalling, M.Sc., Ashot S Harutyunyan, MD, Jelena D. Milosevic, M.Sc., Klaudia Bagienski, M.Sc., Nicole C.C. Them, M.Sc., Veronika Buxhofer-Ausch, Guenther Nirnberger, Leonhard Muellauer, MD, Robert Kralovics, PhD

Blood (2014) 124 (21): 3167.

https://doi.org/10.1182/blood.V124.21.3167.3167

Published: 2014

Journal Articles

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, MSc, Karin Strecker, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Pavla Kadlecova, PhD, Oleh Zagrijtschuk, MD, Christoph Klade, PhD, Richard Greil, MD

Blood (2014) 124 (21): 3177.

https://doi.org/10.1182/blood.V124.21.3177.3177

Published: 2014

Journal Articles

Leukocyte Count Defines Patients on Risk for Thrombotic Complications with Well Controlled Essential Thrombocythemia- Data from a Patient- Registry

Veronika Buxhofer-Ausch, Michael Steurer, Siegfried Sormann, Ernst Schloegl, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2014) 124 (21): 1863.

https://doi.org/10.1182/blood.V124.21.1863.1863

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study

Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across Austria

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis

Influence of Platelet and White Blood Cell Counts until Major Thrombosis: Analysis from a Patient Registry in Essential Thrombocythemia

Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia

Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Leukocyte Count Defines Patients on Risk for Thrombotic Complications with Well Controlled Essential Thrombocythemia- Data from a Patient- Registry

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only